Transforming Ocular therapeutics
Novaliq is a pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics. All first- and best-in-class ocular therapeutics are based on the patented EyeSol® technology. EyeSol® is the first and only water-free technology that overcomes the limitations of water-free eyedrops, improving the topical bioavailability, stability, and safety of traditionally unstable pharmaceutical ingredients. Semifluorinated alkanes (SFAs) form the basis for EyeSol® - scientific know-how made in Germany.
- Worldwide first water-free drug delivery technology (EyeSol®) overcoming limitations of water-based eyedrops
- High product-development competence and integrated processes along the entire value-chain (from the development of the fomulation, the preclinical and clinical stages, all the way to the market)
- Industry-leading product pipeline for Dry Eye Disease based on several new mechanisms of action (MoAs)
- Significant platform value captured in extensive early stage pipeline in glaucoma and retinal diseases
- Intensive and integrative, academic cooperation in the therapeutic area